Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Loring Wolcott & Coolidge Fiduciary Advisors LLP MA

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA reduced its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 29.6% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 32,961 shares of the biopharmaceutical company’s stock after selling 13,855 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Bristol-Myers Squibb were worth $1,611,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Illinois Municipal Retirement Fund grew its position in shares of Bristol-Myers Squibb by 14.0% during the 4th quarter. Illinois Municipal Retirement Fund now owns 614,981 shares of the biopharmaceutical company’s stock valued at $31,555,000 after acquiring an additional 75,592 shares during the period. Aspire Private Capital LLC grew its position in shares of Bristol-Myers Squibb by 230.9% during the 4th quarter. Aspire Private Capital LLC now owns 11,196 shares of the biopharmaceutical company’s stock valued at $575,000 after acquiring an additional 7,812 shares during the period. RWA Wealth Partners LLC grew its position in shares of Bristol-Myers Squibb by 112.3% during the 4th quarter. RWA Wealth Partners LLC now owns 68,703 shares of the biopharmaceutical company’s stock valued at $3,525,000 after acquiring an additional 36,347 shares during the period. Duality Advisers LP grew its position in shares of Bristol-Myers Squibb by 1,700.5% during the 4th quarter. Duality Advisers LP now owns 65,143 shares of the biopharmaceutical company’s stock valued at $3,342,000 after acquiring an additional 61,525 shares during the period. Finally, GUNN & Co INVESTMENT MANAGEMENT INC. acquired a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at about $363,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have recently commented on BMY. Societe Generale cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. StockNews.com lowered shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday, April 15th. Bank of America lowered shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and decreased their price target for the company from $68.00 to $60.00 in a research note on Wednesday, January 3rd. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. Finally, Wells Fargo & Company raised their price target on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research note on Thursday, April 18th. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $61.18.

Bristol-Myers Squibb Trading Up 0.2 %

Shares of BMY stock traded up $0.12 during trading on Tuesday, hitting $49.26. 3,521,191 shares of the stock traded hands, compared to its average volume of 15,450,691. The firm has a market capitalization of $99.84 billion, a P/E ratio of 12.76, a price-to-earnings-growth ratio of 1.48 and a beta of 0.39. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.43 and a quick ratio of 1.31. The firm’s fifty day moving average price is $51.22 and its 200-day moving average price is $51.38. Bristol-Myers Squibb has a 52-week low of $47.58 and a 52-week high of $70.93.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.55 by $0.15. The firm had revenue of $11.48 billion for the quarter, compared to analyst estimates of $11.19 billion. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. The business’s revenue for the quarter was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.82 EPS. As a group, research analysts forecast that Bristol-Myers Squibb will post 6.63 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 4.87%. The ex-dividend date is Thursday, April 4th. Bristol-Myers Squibb’s payout ratio is presently 62.18%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.